NCT04481763View on ClinicalTrials.gov

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

August 30, 2024

Study Completion Date

October 1, 2026

Conditions
Triple-Negative Breast Cancer
Interventions
DRUG

Camrelizumab

Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)

RADIATION

radiotherapy

radiotherapy

Trial Locations (1)

Unknown

RECRUITING

Chunling Jiang, Nanchang

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER

NCT04481763 - A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | Biotech Hunter | Biotech Hunter